ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Francina Agosti contributed 14 entries already.
Parisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.
Paris-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target protein degradation, a field that is attracting significant attention for its potential to treat previously intractable diseases.
The European Innovation Council (EIC) has funded the collaborative GLIOBREAK project, bringing together Swedish biotech Beactica Therapeutics and the Belgian KU Leuven Institute for Single-Cell Omics (LISCO) to advance Beactica’s small-molecule candidate, BEA-17, as a precision immunotherapy for glioblastoma, the most common and aggressive form of brain cancer, which currently has limited treatment options.
Stockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab).
Swedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases.
French biotech company Sensorion announced today a €60 million (about $72 million) reserved offering including a €20 million strategic investment from Sanofi. The remaining €40 million subscribed by existing shareholders Redmile Group, Artal (advised by Invus), and Sofinnova Partners, alongside new investors including Cormorant Asset Management, Coastlands Capital, and Sphera Healthcare, which are leading US Healthcare Specialists funds.
The transatlantic venture firm Epidarex Capital has reached a first close of more than $145 million (approximately €121.6 million) to focus on company creation and early-stage investments across the UK and the US.
The U.K. biotech Ellipses Pharma, which develops cancer therapeutics, announced a collaboration and licensing agreement with China-based Innolake Biopharm Co. Ltd to develop a clinical-stage, first-in-class antibody–drug conjugate (ADC), EP0028, for solid tumors.
The French preclinical-stage biotech ErVimmune closed a €17 million series A round to bring its lead candidate cancer vaccine into the clinic.
French gene therapy research institute Genethon announced it has signed an exclusive global license with AskBio that allows the company to use Genethon-patented technology incorporated in AB-1009, an experimental gene therapy for Pompe disease.